MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

Annals of Oncology 2026 Open access

Read full text
Authors: M. Aldea, S. Lenahan, M-A. Locquet, L. Liao, M. Gasparro, P.C. Gokhale, M.-R. Ghigna, D.N. Ionescu, I. Odintsov, K. Ngo, X. Wang, S. Aziz
+36 more F. Pecci, E. Garbo, E. Ivanova, S. Nakazawa, J. Kulesza, J.A. Tsai, L. Zullo, J. W. Lee, M. Zielinska, S. Simon, D. Han, A. Marinello, G. Li, G. Rossato de Almeida, J. Huang, F. Paoloni, E. Gariazzo, V. Santo, J. Remon, J.A. Marks, J. LoPiccolo, N. Florez, M. Nishino, B. Ricciuti, J. L. Luo, D.A. Barbie, D. Planchard, J.K. Rotow, F. Barlesi, R.P. Graf, W.W. Feng, B. Besse, C. Paweletz, L. Sholl, A.T. Shaw, P.A. Jänne
DOI: 10.1016/j.annonc.2026.03.001
Cited by: 8
References: 30

Fields of Study & Subjects

Cancer-related gene regulation Nuclear Receptors and Signaling Blood Coagulation and Thrombosis Mechanisms

Publication details

Journal / source
Annals of Oncology
Publisher
Elsevier BV
Volume
37
Issue
7
Pages
946–959
Publication date
14 March 2026
Language
EN